Frovatriptan – the gentle one

Frovatriptan (Allegro) is currently the newest triptan and will be available as a 2.5 mg film-coated tablet from autumn 2002. The recommended single dose is 2.5 mg frovatriptan. If the migraine recurs after an initial improvement in the form of recurring headaches, a second dose can be taken, provided that at least 2 hours have passed after taking the first dose. The total daily dose should not exceed 5 mg of frovatriptan per day.

Special features at a glance

  • Frovatriptan differs from other triptans in that it binds to additional serotonin receptors.
  • On the one hand, the substance binds strongly to 5HT1B/D receptors like the other triptans, but in contrast to sumatriptan, frovatriptan also binds to 5HT7 receptors.
  • These receptors are located particularly on the blood vessels of the heart.
  • Their activation causes vasodilation, meaning blood flow is not reduced. In a study, even with an extreme 40-fold overdose of 100 mg frovatriptan, no significant side effects were found in the area of ​​the cardiovascular system in healthy people. Such side effects in the cardiovascular system could theoretically be less likely to occur in migraine patients.
  • Frovatriptan is slowly absorbed in the gastrointestinal tract. After 2 hours, 38% and 37% of patients who received 2.5 and 5 mg frovatriptan, respectively, showed significant improvement in migraine headaches.
  • After 4 hours the improvement rate is 68% and 67%.
  • Frovatriptan has a long-lasting effect, making the drug particularly suitable for long-lasting attacks lasting two to three days.
  • The likelihood of headaches recurring after initial effectiveness is low.